ABL Europe to manufacture Themis SARS-CoV-2 vaccine in France

By The Science Advisory Board staff writers

May 11, 2020 -- Biopharmaceutical company Themis and contract development and manufacturing organization ABL Europe announced that they have signed an agreement to manufacture a SARS-CoV-2 vaccine candidate in preparation for clinical trials.

The Themis vaccine candidate is being developed using measles virus vaccine platform technology, which is licensed exclusively to Themis by the Insitut Pasteur in Paris. ABL will manufacture the vaccine at its specialized facilities located in Strasbourg and Lyon, France.

Themis is actively collaborating with Institut Pasteur, the Center for Vaccine Research at the University of Pittsburgh, and the Coalition for Epidemic Preparedness Innovations (CEPI) to develop the COVID-19 vaccine candidate. CEPI initially has invested $4.9 million for its development.

NIH leadership discusses COVID-19 vaccine collaborations
Public-private partnerships could help meet the unprecedented need to manufacture and distribute safe and effective COVID-19 vaccines around the globe,...
Inovio expands manufacturing for COVID-19 vaccine
Inovio has partnered with German contract manufacturer Richter-Helm BioLogics to produce large-scale quantities of Inovio's investigational DNA vaccine.
J&J announces manufacturing collaboration for COVID-19 vaccine
Johnson & Johnson, a Janssen Pharmaceuticals company, announced on April 24 a collaboration with Emergent BioSolutions to support the manufacturing...

Copyright © 2020 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter